Trials / Terminated
TerminatedNCT05966740
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
Safety and Effectiveness of Pradaxa Oral Pellet Formulation for Treatment of Acute Venous Thromboembolic Events (VTE) and/or for Risk Reduction of Recurrence of VTE in Pediatric Patients Aged 3 Months to Less Than 12 Years in a Real World Setting: a Prospective Non-interventional Study Conducted in the United States
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 3 Months – 12 Years
- Healthy volunteers
- Not accepted
Summary
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Conditions
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2025-04-28
- Completion
- 2025-04-28
- First posted
- 2023-08-01
- Last updated
- 2025-09-04
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05966740. Inclusion in this directory is not an endorsement.